IKT Stock — Inhibikase Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.30

Market cap

$320.9M

Cash

$159.0M

Enterprise value

$161.9M

Balance sheet

Cash	$159.0M
Debt	$0.0M
Net cash	$159.0M
Enterprise value	$161.9M
Basic shares	132.0M shares
Fully diluted shares	190.9M shares
Fully diluted market cap	$439.2M
Cash per share	$1.20

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IKT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	IKT-001	Phase 3	Pulmonary Arterial Hypertension	—
Aug 11 - Sep 22	IKT-001	Phase 3	Pulmonary Arterial Hypertension (PAH)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IKT-001

Phase 3 · Active Modality: Small molecule (oral prodrug)

Target Abelson tyrosine kinase / type III receptor tyrosine kinases

Indications

Pulmonary arterial hypertension (PAH) (Phase 3)

Status note Lead candidate: prodrug of imatinib mesylate (FDA Orphan Drug Designation for PAH). IMPROVE-PAH single pivotal global Phase 3 enrolling.

Risvodetinib

Stage not disclosed · Active Modality: Small molecule

Aliases IKT-148009

Partnerships ABLi Therapeutics (license agreement, May 5, 2025): exclusive, sub-licensable, royalty-bearing global license to develop, manufacture and commercialize risvodetinib; ABLi solely responsible for all further development and commercialization and bears all costs

Indications

not disclosed (Stage not disclosed)

Status note Discontinued by Inhibikase and out-licensed to ABLi; ABLi responsible for all further development. Parkinson's disease appears only as a risk-factor heading in the 10-Q without an explicit filing link to risvodetinib, so indication is left as not disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	IKT-001
Lead indication	Pulmonary Arterial Hypertension
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07365332	Phase 3	Recruiting	Sponsor	Inhibikase Therapeutics	—	Pulmonary Arterial Hypertension	—
NCT07632898	Phase 3	Not yet recruiting	Sponsor	Inhibikase Therapeutics	—	Pulmonary Arterial Hypertension (PAH)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Inhibikase Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	7,387,205	+780,633	0.70%	2026-08-14
Sphera Biotech	649,309	+649,309	0.19%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

IKT — Inhibikase Therapeutics Inc.